Table 1.
Expression of ALK Protein(s) in Human Lymphohemopoietic Neoplasms
| Lymphoma*/Leukemia | Number of cases (N = 550) | ALK-positive tumor cells |
|---|---|---|
| Non-Hodgkin’s lymphomas | ||
| B cell derived | ||
| Pre-B-cell acute lymphoblastic leukemia | 20 | 0 /20 |
| Small lymphocytic/B-cell chronic lymphocytic leukemia | 45 | 0 /45 |
| Hairy cell leukemia | 15 | 0 /15 |
| Mantle cell lymphoma | 22 | 0 /22 |
| Marginal zone lymphoma | 15 | 0 /15 |
| Follicle center lymphoma | 56 | 0 /56 |
| Diffuse large cell lymphoma | 100 | 0 /100 |
| Burkitt’s lymphoma | 13 | 0 /13 |
| T cell derived | ||
| Acute lymphoblastic leukemia | 8 | 0 /8 |
| Mycosis fungoides | 10 | 0 /10 |
| Peripheral T-cell lymphoma | 30 | 0 /30 |
| Anaplastic large cell lymphoma | 100 | 60 /100 |
| Hodgkin’s disease | ||
| Nodular, lymphocyte predominance | 10 | 0 /10 |
| Nodular sclerosis | 45 | 0 /45 |
| Mixed cellularity | 21 | 0 /21 |
| Chronic and acute myeloid disorders | ||
| Chronic myeloid leukemia | 10 | 0 /10 |
| Idiopathic myelofibrosis | 5 | 0 /5 |
| Polycythemia rubra vera | 5 | 0 /5 |
| Acute myeloid leukemias† | 20 | 0 /20 |
All staining results were obtained with the ALKc mAb. ALCLs were stained in parallel with the ALKc and ALK1 antibodies.
*Categorized according to the REAL classification. 43
†M1 (n = 2), M2 (n = 6), M3 (n = 5), M4 (n = 5), M5 (n = 2).